- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 28
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 28, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 28.
Number 5: A recent study concluded that reference pricing can help drive down the cost of drugs for health plans, but can raise out-of-pocket costs for patients.
Number 4: Amgen and Sandoz have filed new briefs stating their positions on how the lower courts should address their claims after the Supreme Court’s recent ruling in Sandoz v Amgen.
Number 3: Ireland’s National Cancer Control Programme has issued new guidance on the use of biosimilar medicines in the treatment of cancer.
Number 2: Drug maker Biocon has announced that the FDA will delay a decision on its trastuzumab biosimilar by 3 months.
And Number 1: The FDA has approved Boehringer Ingelheim’s adalimumab biosimilar. Cyltezo is the second FDA-approved biosimilar of the blockbuster reference drug, Humira.
Finally, last week, our newsletter asked you to share your thoughts about whether drug pricing contracts between reference product developers and payers are bad news for biosimilars. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
